Table 2.
TILs and immune checkpoint biomarker expression in UPS.
| Overall N = 105 | Primary n = 46 | Recurrence n = 34 | Metastasis n = 25 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Biomarker | n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | p-value* |
| Tumor infiltrating lymphocytes (cells/mm2) | |||||||||
| CD3 | 105 | 285 (82-615) |
46 | 283 (77-460) |
34 | 296 (82-551) |
25 | 280 (112-862) |
0.379 |
| CD8 | 104 | 131 (42-360) |
46 | 120 (40-234) |
33 | 126 (43-452) |
25 | 158 (53-565) |
0.220 |
| CD20 | 99 | 0 (0-3) | 44 | 0.6 (0-2) | 31 | 0 (0-2) | 24 | 1.5 (0-4) | 0.379 |
| CD163 | 103 | 2640 (1728-3501) |
46 | 2666 (1689-3467) |
33 | 2861 (1929-3667) |
24 | 4215.6 (1415-2951) |
0.429 |
| Immune-checkpoint biomarkers: | |||||||||
| Stimulatory (cells/mm2) | |||||||||
| ICOS | 99 | 2 (0-13) | 43 | 3.5 (0-12) | 32 | 2.5 (0-18) | 24 | 3.4 (0-12) | 0.629 |
| OX40 | 101 | 0 (0-2) | 44 | 0 (0-1) | 32 | 0.3 | 25 | 0 (0-2) | 0.674 |
| Inhibitory (cells/mm2) | |||||||||
| LAG3 | 102 | 0 (0-0) | 44 | 0(0-0) | 33 | 0 (0-18) | 25 | 0 (0-0) | NA |
| IDO1 | 103 | 0 (0-0) | 45 | 0 (0-0) | 33 | 0 (0-0) | 25 | 0 (0-0) | 0.462 |
| PD1 | 104 | 36 (8-125) | 46 | 34.5 (6-107) | 33 | 37 (11-81) | 25 | 34.5 (13-158) | 0.401 |
| Biomarkers expression by malignant cells(%) | |||||||||
| PD-L1 | 104 | 0 (0-0) | 45 | 0 (0-0) | 34 | 0 (0-0) | 25 | 0 (0-0) | 0.462 |
| CD73 | 102 | 56 (1-85) | 44 | 58 (1-80) | 33 | 80 (10-86) | 25 | 15 (1-85) | 0.276 |
| CD39 | 105 | 5 (0.5-25) | 46 | 2 (0-15) | 34 | 8 (0.5-39) | 25 | 10.5 (1-23) | 0.402 |
*Kruskal-Wallis tests.
IQR, interquartile range; NA, Not applicable; TILs, tumor infiltrating lymphocytes; UPS, undifferentiated pleomorphic sarcoma.